Neuralgene logo

Neuralgene

Neuralgene is a biotechnology company with the focus of developing gene therapy for Neural disorders. Neuralgenes main development is PRCN-829, an AAV based gene therapy for the treatment of ALS.

The company is driven by a Radiologist with a passion for gene and cellular therapies Jason R. Williams, MD. The company is working in conjunction with Helica Labs in Playa Del Carmen, Mexico for the production of its gene therapy.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://neuralgene.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Bogota
Columbia
Email
Contact Number
251-943-9409

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Neuralgene drug discovery is based on neurotropic AAV-based gene therapy platform. AAV9 viral vector delivers multiple genes, which include Factor H (a regulator of complement activity), neural growth factors and regulators of TDP-43, to the neural cells.